Applied dna announces preliminary estimated first fiscal quarter 2021 revenues in the range of $1.3 million to $1.6 million

Stony brook, n.y.--(business wire)---- $apdn #covid19--applied dna sciences, inc. (nasdaq: apdn) (“applied dna” or the “company”), a leader in polymerase chain reaction (pcr)-based dna manufacturing, announced today that it expects revenues for the first fiscal quarter of 2021 ended december 31, 2020, to be in the range of $1.3 million to $1.6 million compared to revenues of $314,000 in the fourth quarter of fiscal 2020. the strong sequential growth in quarterly revenues is driven principally by demand for safeci
APDN Ratings Summary
APDN Quant Ranking